Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.42 |
| ▸ | WNT3A | P56704 | 4/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168979 | 0.84 | CTNNB1 (0.57) | PTPN1GSK3BLMNAGAACTNNB1 | |
| SCHEMBL30013031 | 0.84 | CTNNB1 (0.57) | PTPN1GSK3BLMNAGAACTNNB1 | |
| SCHEMBL5375712 | 0.83 | YAP1 (0.46) | GSK3BLMNAGAACTNNB1WNT3A | |
| SCHEMBL1198865 | 0.83 | CTSS (0.48) | PTPN1GSK3BLMNAGAACTNNB1 | |
| SCHEMBL5362885 | 0.83 | LMNA (0.42) | LMNAGAACTNNB1WNT3ATAS2R14 | |
| SCHEMBL7784257 | 0.81 | PTPN1 (0.45) | PTPN1GSK3BLMNAPOLB | |
| SCHEMBL9526234 | 0.81 | CTSS (0.49) | PTPN1GSK3BCTSS | |
| SCHEMBL23041398 | 0.80 | LMNA (0.48) | LMNAGAACTNNB1WNT3ATAS2R14 | |
| SCHEMBL1195140 | 0.78 | TAS2R14 (0.51) | LMNAGAATAS2R14KCNK3KCNK9 | |
| SCHEMBL5358162 | 0.78 | PTPN1 (0.48) | PTPN1GSK3BLMNAGAACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189863-B2 | Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-13 | — | — | US | disclosed |
| US-20060128976-A1 | Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-7053248-B2 | brominating a trifluoromethyl-substituted acetophenone with bromine in presence of acetalization agent that is an alkylene diol, reacting the brominated acetal with metal alkoxide thereby converting brominated acetal into ether, hydrolyzing ether in presence of acid catalyst to remove an acetal group | CENTRAL GLASS COMPANY, LIMITED (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20050171363-A1 | Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128976-A1 | Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives | HACL2, BOLA2; BOLA2B, ADH5 | PTPN1 3805/4885GSK3B 3980/4885LMNA 2115/4885 |
| US-20050171363-A1 | Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives | HACL2, BOLA2; BOLA2B, ADH5 | PTPN1 3805/4885GSK3B 3980/4885LMNA 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.